Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Go back to Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
(NASDAQ: KURA) Delayed: 9.96 -0.02 (0.2%)
Previous Close $9.98    52 Week High $8.90 
Open $10.04    52 Week Low $2.50 
Day High $10.18    P/E N/A 
Day Low $9.93    EPS $0.00 
Volume 386,391